AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | +2.65% | +7.08% | -9.22% |
05-16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
05-02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.22% | 264M | |
+11.91% | 227B | |
+15.46% | 197B | |
+18.58% | 141B | |
+30.36% | 110B | |
+0.65% | 64.15B | |
+17.74% | 53.72B | |
+5.82% | 51.75B | |
+11.23% | 45.2B | |
+5.73% | 37.37B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Provides Revenue Guidance for the Year 2024